Hepatic encephalopathy

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
N Neurology/Psychiatry (ATC N) 1
ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Salix Pharmaceuticals Inc. Commercial
    RIFAXIMIN
    2022-502899-23-00 8 countries 2024 n=222 Orphan
    Ended

Phase II

1 trial
  • Versantis AG Commercial
    CITRIC ACID, ANHYDROUS PH. EUR.
    2025-521029-34-00 4 countries 2025 n=30
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Versantis AG Commercial 1 Phase II 0
Salix Pharmaceuticals Inc. Commercial 1 Phase III 0
New trials by year
2024
1
2025
1
← All indication landscapes